Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells

@article{Gatto2018CellSI,
  title={Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells},
  author={Federico Gatto and Marica Arvigo and Jessica Amar{\`u} and Claudia Campa{\~n}a and Francesco Cocchiara and Giulia Canciani Graziani and Eleonora Bruzzone and Massimo Giusti and Mara Boschetti and Diego Ferone},
  journal={Pituitary},
  year={2018},
  volume={22},
  pages={89-99}
}
BackgroundPasireotide is a second-generation somatostatin (SRIF) receptor ligand (SRL), approved for medical treatment of acromegaly and Cushing’s disease (CD). The molecule is a stable cyclohexapeptide synthetized based on SRIF structure. Differently from first-generation SRLs (e.g. octreotide), preferentially binding somatostatin receptor (SST) subtype 2 (SST2), pasireotide has high affinity for multiple SSTs (SST5 > SST2 > SST3 > SST1). Interestingly, early preclinical studies demonstrated… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 60 REFERENCES

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

  • The Journal of clinical endocrinology and metabolism
  • 2017
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL